Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$5.56
$4.65
$1.43
$5.69
$776.53M0.761.98 million shs1.94 million shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$12.90
$11.22
$1.21
$13.69
$738.69M0.071.56 million shs1.18 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.49
$14.09
$6.69
$16.73
$780.73M1.88791,939 shs556,530 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$12.34
$12.66
$10.03
$69.97
$196.71M1.64567,705 shs326,446 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%+11.20%+18.05%+32.38%+283.45%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.00%-1.38%+18.24%+96.65%+923.81%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%-3.18%-4.15%+76.62%+108.20%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
0.00%-6.66%+3.87%-11.22%-64.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$5.56
$4.65
$1.43
$5.69
$776.53M0.761.98 million shs1.94 million shs
Climb Bio, Inc. stock logo
CLYM
Climb Bio
$12.90
$11.22
$1.21
$13.69
$738.69M0.071.56 million shs1.18 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$15.49
$14.09
$6.69
$16.73
$780.73M1.88791,939 shs556,530 shs
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$12.34
$12.66
$10.03
$69.97
$196.71M1.64567,705 shs326,446 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%+11.20%+18.05%+32.38%+283.45%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
0.00%-1.38%+18.24%+96.65%+923.81%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%-3.18%-4.15%+76.62%+108.20%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
0.00%-6.66%+3.87%-11.22%-64.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.13
Buy$11.50106.83% Upside
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3.07
Buy$21.7368.43% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$15.11-2.45% Downside
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
3.00
Buy$24.0094.49% Upside

Current Analyst Ratings Breakdown

Latest TNXP, CYRX, ACRS, and CLYM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
Initiated CoverageStrong-Buy$26.00
6/24/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Reiterated RatingSell (D-)
6/24/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Reiterated RatingBuy$20.00
6/24/2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
UpgradeStrong-Buy
6/12/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Reiterated RatingOutperform$17.00
6/11/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Boost Price TargetBuy$19.00 ➝ $20.00
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$13.50
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingHold$13.00
6/8/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Initiated CoverageBuy$35.00
6/8/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Initiated CoverageBuy$35.00
6/8/2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
Reiterated RatingBuy$19.00
(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$8.37M92.81N/AN/A$0.85 per share6.54
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/A$3.36 per shareN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$182.94M4.27N/AN/A$9.19 per share1.69
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
$13.11M15.00N/AN/A$19.17 per share0.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3511.47N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)

Latest TNXP, CYRX, ACRS, and CLYM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million
5/7/2026Q1 2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million
5/7/2026Q1 2026
Climb Bio, Inc. stock logo
CLYM
Climb Bio
-$0.26-$0.20+$0.06-$0.20N/AN/A
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
4.03
4.03
Climb Bio, Inc. stock logo
CLYM
Climb Bio
N/A
27.86
27.86
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
N/A
6.99
6.86

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
69.76%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
82.26%

Insider Ownership

CompanyInsider Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
4.80%
Climb Bio, Inc. stock logo
CLYM
Climb Bio
2.60%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100139.66 million132.96 millionOptionable
Climb Bio, Inc. stock logo
CLYM
Climb Bio
957.26 million55.77 millionN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
Tonix Pharmaceuticals Holding Corp. stock logo
TNXP
Tonix Pharmaceuticals
5015.94 million15.62 millionNot Optionable

Recent News About These Companies

Why Is TNXP Stock Rising Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$5.56 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$5.58 +0.02 (+0.36%)
As of 07/2/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Climb Bio stock logo

Climb Bio NASDAQ:CLYM

$12.90 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$12.90 0.00 (0.00%)
As of 07/2/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$15.49 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$15.50 +0.01 (+0.06%)
As of 07/2/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Tonix Pharmaceuticals stock logo

Tonix Pharmaceuticals NASDAQ:TNXP

$12.34 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$12.25 -0.09 (-0.73%)
As of 07/2/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.